High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

AIMS: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. BACKGROUND: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its use is complicated by opportunistic JCV infectio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Neurol Disord
Autors principals: Dwyer, Christopher M., Jokubaitis, Vilija G., Stankovich, Jim, Baker, Josephine, Haartsen, Jodi, Butzkueven, Helmut, Cartwright, Adriana, Shuey, Neil, Fragoso, Yara Dadalti, Rath, Louise, Skibina, Olga, Fryer, Kylie, Butler, Ernest, Coleman, Jennifer, MacIntrye, Jennifer, Macdonell, Richard, van der Walt, Anneke
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053827/
https://ncbi.nlm.nih.gov/pubmed/33948117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286421998915
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars